TENTECH announced on the 23rd that its self-developed monopolar RF aesthetic medical device, '10THERMA,' has obtained product approval from the health authorities of Russia and Kazakhstan, and is shipping its initial batch to supply the local markets.

Through this approval, TENTECH has secured a foundation for product supply in Kazakhstan, a major market within Russia and the CIS (Commonwealth of Independent States) region. Following the approval, the company is shipping its first volume in accordance with a supply contract with a local partner, beginning its full-scale export operations.

In Russia and the broader CIS region, demand for aesthetic medical procedures, such as lifting and skin elasticity treatments, has recently been rising, prompting a continuous influx of global aesthetic medical device companies. Domestic aesthetic medical device manufacturers are also pushing to enter these local markets and expand their distribution networks.

10THERMA is an aesthetic medical device utilizing a 6.78MHz monopolar radiofrequency (RF) technology with a maximum output of 400W. Equipped with proprietary design technologies, including a smart cooling system and impedance matching, it is designed to deliver energy evenly and stably during procedures.

With the shipment of the initial batch, TENTECH plans to expand its engagement with local medical professionals. The company will host academic seminars and hands-on workshops targeting Key Opinion Leaders (KOLs) and plans to participate in local medical device exhibitions.

Han Dong-ok, CEO of TENTECH, stated, "Obtaining approval in the Russian and Kazakhstani markets, which maintain strict certification standards, is an achievement that objectively validates the technological prowess of '10THERMA'." He added, "As we approach the milestone of 1,000 units sold both domestically and internationally, we will use this export as an opportunity to accelerate the expansion of our market share in the CIS region."

TENTECH has secured numerous overseas medical device certifications, including FDA, ANVISA, TGA, MDSAP, and CE MDR. Following its expansion into countries like the U.S., Thailand, and Brazil, the company plans to use this entry into the CIS market to further broaden its global direct and indirect distribution networks and increase the proportion of its overseas sales.